GTBP Quote, Financials, Valuation and Earnings

Geron Corp. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -39.02%. GT Biopharma, Inc.'s return on equity of -626.24% beat Geron Corp.'s return on equity of -29.65%.

GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1384.51%. On the other hand Geron Corp. has an analysts' consensus of $3.60 which suggests that it could grow by 122.22%. Given that GT Biopharma, Inc. has higher upside potential than Geron Corp., analysts believe GT Biopharma, Inc. is more attractive than Geron Corp..

GT Biopharma, Inc. has a beta of 1.209, which suggesting that the stock is 20.887% more volatile than S&P 500. In comparison Geron Corp. has a beta of 0.620, suggesting its less volatile than the S&P 500 by 38.038%.

GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Geron Corp. pays out -- of its earnings as a dividend.

GT Biopharma, Inc. quarterly revenues are --, which are smaller than Geron Corp. quarterly revenues of $47.2M. GT Biopharma, Inc.'s net income of -$3.1M is higher than Geron Corp.'s net income of -$18.4M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Geron Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 5.55x for Geron Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Lyell Immunopharma, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of -258973.33%. GT Biopharma, Inc.'s return on equity of -626.24% beat Lyell Immunopharma, Inc.'s return on equity of -86.7%.

GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1384.51%. On the other hand Lyell Immunopharma, Inc. has an analysts' consensus of $29.67 which suggests that it could grow by 30.63%. Given that GT Biopharma, Inc. has higher upside potential than Lyell Immunopharma, Inc., analysts believe GT Biopharma, Inc. is more attractive than Lyell Immunopharma, Inc..

GT Biopharma, Inc. has a beta of 1.209, which suggesting that the stock is 20.887% more volatile than S&P 500. In comparison Lyell Immunopharma, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lyell Immunopharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Lyell Immunopharma, Inc. pays out -- of its earnings as a dividend.

GT Biopharma, Inc. quarterly revenues are --, which are smaller than Lyell Immunopharma, Inc. quarterly revenues of $15K. GT Biopharma, Inc.'s net income of -$3.1M is higher than Lyell Immunopharma, Inc.'s net income of -$38.8M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Lyell Immunopharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 82,351.11x for Lyell Immunopharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of 21.74%. GT Biopharma, Inc.'s return on equity of -626.24% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1384.51%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $859.58 which suggests that it could grow by 9.43%. Given that GT Biopharma, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe GT Biopharma, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

GT Biopharma, Inc. has a beta of 1.209, which suggesting that the stock is 20.887% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

GT Biopharma, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. GT Biopharma, Inc.'s net income of -$3.1M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus 5.95x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SELLAS Life Sciences Group, Inc. has a net margin of -- compared to GT Biopharma, Inc.'s net margin of --. GT Biopharma, Inc.'s return on equity of -626.24% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.

GT Biopharma, Inc. has a consensus price target of $8.00, signalling upside risk potential of 1384.51%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 83.2%. Given that GT Biopharma, Inc. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe GT Biopharma, Inc. is more attractive than SELLAS Life Sciences Group, Inc..

GT Biopharma, Inc. has a beta of 1.209, which suggesting that the stock is 20.887% more volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.273, suggesting its more volatile than the S&P 500 by 127.327%.

GT Biopharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. GT Biopharma, Inc. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.

GT Biopharma, Inc. quarterly revenues are --, which are smaller than SELLAS Life Sciences Group, Inc. quarterly revenues of --. GT Biopharma, Inc.'s net income of -$3.1M is higher than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, GT Biopharma, Inc.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for GT Biopharma, Inc. is 59.35x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.